Ketamine as a rapid antidepressant: the debate and implications
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Summary: Ketamine, a synthetic derivative of phencyclidine, is a commonly misused party drug that is restricted in high-income countries because of its addictive potential. Ketamine is also used as an anaesthetic in human and veterinary medicine. In the 1990s, research using ketamine to study the pathophysiology of schizophrenia was terminated owing to ethical concerns. Recently, controversy surrounding the drug has returned, as researchers have demonstrated that intravenous ketamine infusion has a rapid antidepressant effect and have therefore proposed ketamine as a novel antidepressant. This article debates the question of ketamine as an antidepressant, considering the drug's addictive potential, ethical concerns about prescribing a hallucinogen, the evidence base and motives behind ketamine trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926 · cited 1×
“These mechanisms might include its effect on mammalian target of rapamycin (mTOR) receptors (Li 2011b), BDNF (Autry 2011), the dopamine system (Tan 2012), sigma receptors (Robson 2012) and nicotinic acetylcholine receptors (Nishitani 2014).”
Moghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793 · cited 3×
“In animal studies, subanaesthetic doses were associated with acute increases in extracellular glutamate and dopamine in the prefrontal cortex (Moghaddam 1997) and anterior cingulate cortex (Stone 2012), leading to excitatory neurotransmission.”
Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030392 · Cited by 1,205
Diazgranados, N., Ibrahim, L., Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., Kammerer, W. A., Quezado, Z., Luckenbaugh, D. A., Salvadore, G., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.90 · Cited by 963 · cited 2×
“Fifth, DiazGranados et al (2010a) reported rapid resolution of suicidal ideation after a single infusion of ketamine.”
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders
Sanacora, G., Zarate, C. A., Krystal, J. H., & Manji, H. K. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2462 · Cited by 894
Zarate, C. A., Brutsche, N. E., Ibrahim, L., Franco-Chaves, J., Diazgranados, N., Cravchik, A., Selter, J., Marquardt, C. A., Liberty, V., & Luckenbaugh, D. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.12.010 · Cited by 811 · cited 3×
“A principal investigator at NIMH is listed as co-inventor of another patent application for the use of ketamine in depression (WO 2013056229 A1), although he has assigned his rights on the patent to the US government (noted in Zarate 2012).”
Treatment-resistant depression: therapeutic trends, challenges, and future directions
Al-harbi (2012) · Patient Preference and Adherence · doi:10.2147/ppa.s29716 · Cited by 796 · cited 1×
“Around one-third of patients who are refractory to initial treatment do not respond to other antidepressants and combined treatment (Al-Harbi 2012).”
Murrough, J. W., Perez, A. M., Pillemer, S., Stern, J., Parides, M. K., aan het Rot, M., Collins, K. A., Mathew, S. J., Charney, D. S., & Iosifescu, D. V. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.06.022 · Cited by 786
Safety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression
aan het Rot, M., Collins, K. A., Murrough, J. W., Perez, A. M., Reich, D. L., Charney, D. S., & Mathew, S. J. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.08.038 · Cited by 690
R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects
Yang, C., Shirayama, Y., Zhang, J.-C., Ren, Q., Yao, W., Ma, M., Dong, C., & Hashimoto, K. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.136 · Cited by 605
Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression.
Newport, D. J., Carpenter, L. L., McDonald, W. M., Potash, J. B., Tohen, M., Nemeroff, C. B., & The APA Council of Research Task Force on Novel Biomarkers and Treatments (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15040465 · Cited by 598 · cited 1×
“…Association task force has warned of the misuse potential and risk of neurotoxicity with regular administration of ketamine in clinical settings (Newport 2015), most other professional and regulatory bodies, including the Royal College of Psychiatrists, the Commission on Human Medicines and the…”
DiazGranados, N., Ibrahim, L. A., Brutsche, N. E., Ameli, R., Henter, I. D., Luckenbaugh, D. A., Machado-Vieira, R., & Zarate, C. A. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05327blu · Cited by 564
A Randomized Controlled Trial of Intranasal Ketamine in Major Depressive Disorder
Lapidus, K. A. B., Levitch, C. F., Perez, A. M., Brallier, J. W., Parides, M. K., Soleimani, L., Feder, A., Iosifescu, D. V., Charney, D. S., & Murrough, J. W. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.03.026 · Cited by 480
Taylor, M. J., Freemantle, N., Geddes, J. R., & Bhagwagar, Z. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.11.1217 · Cited by 406
Liu, R.-J., Lee, F. S., Li, X.-Y., Bambico, F., Duman, R. S., & Aghajanian, G. K. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.09.030 · Cited by 403
Morgan, C. J. A., Muetzelfeldt, L., & Curran, H. V. (2010) · Addiction · doi:10.1111/j.1360-0443.2009.02761.x · Cited by 373
Ketamine administration in depressive disorders: a systematic review and meta-analysis
Fond, G., Loundou, A., Rabu, C., Macgregor, A., Lançon, C., Brittner, M., Micoulaud-Franchi, J.-A., Richieri, R., Courtet, P., Abbar, M., et al. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3664-5 · Cited by 339
Ibrahim, L., DiazGranados, N., Franco-Chaves, J., Brutsche, N., Henter, I. D., Kronstein, P., Moaddel, R., Wainer, I., Luckenbaugh, D. A., Manji, H. K., et al. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.338 · Cited by 309 · cited 2×
“In trials, combined riluzole and ketamine treatment did not prevent relapse of depression (Mathew 2010) or alter the course of antidepressant response to ketamine (Ibrahim 2012).”
Stone, J. M., Dietrich, C., Edden, R., Mehta, M. A., De Simoni, S., Reed, L. J., Krystal, J. H., Nutt, D., & Barker, G. J. (2012) · Molecular Psychiatry · doi:10.1038/mp.2011.171 · Cited by 295
The use of ketamine as an antidepressant: a systematic review and meta‐analysis
Coyle, C. M., & Laws, K. R. (2015) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2475 · Cited by 279
Ketamine as a Novel Antidepressant: From Synapse to Behavior
Murrough, J. W. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.244 · Cited by 172 · cited 1×
“Current antidepressants are associated with poor response and lack clinical effectiveness (Murrough 2012; Thakurta 2012; Hasselmann 2014) This assumption is based on overestimates of the prevalence of treatment-resistant depression (Quevedo 2009) and underestimates of the effectiveness of current treatment: 9–10% of p…”
Sanacora, G., & Schatzberg, A. F. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.261 · Cited by 160
Antidepressant actions of ketamine: from molecular mechanisms to clinical practice
Monteggia, L. M., & Zarate, C. (2015) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2014.12.004 · Cited by 149 · cited 1×
“Memantine is a non-competitive NMDA receptor antagonist, but it does not have a rapid anti depressant effect (Monteggia 2015).”
Reduced dorsal prefrontal gray matter after chronic ketamine use
Liao, Y., Tang, J., Corlett, P. R., Wang, X., Yang, M., Chen, H., Liu, T., Chen, X., Hao, W., & Fletcher, P. C. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.08.030 · Cited by 145
The Nonmedical Use of Ketamlne, Part Two: A Review of Problent Use and Dependence
Jansen, K. L. R., & Darracot-Cankovic, R. (2001) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2001.10400480 · Cited by 137
Lee, E. E., Della Selva, M. P., Liu, A., & Himelhoch, S. (2015) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2015.01.003 · Cited by 124
Morgan, C. J. A., Dodds, C. M., Furby, H., Pepper, F., Fam, J., Freeman, T. P., Hughes, E., Doeller, C., King, J., Howes, O., et al. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00149 · Cited by 110
Psychometric properties and clinical utility of the Scale for Suicidal Ideation (SSI) in adolescents
Holi, M. M., Pelkonen, M., Karlsson, L., Kiviruusu, O., Ruuttu, T., Heilä, H., Tuisku, V., & Marttunen, M. (2005) · BMC Psychiatry · doi:10.1186/1471-244x-5-8 · Cited by 87
Hippocampal volume and the rapid antidepressant effect of ketamine
Abdallah, C. G., Salas, R., Jackowski, A., Baldwin, P., Sato, J. R., & Mathew, S. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114544776 · Cited by 78 · cited 1×
“Predictors of poor response included a large hippocampus (Abdallah 2014 • Psychiatrists need to be mindful that most ketamine trials did not specify which previous treatments patients had received and that the effect of ketamine was compared with placebo or midazolam, but not with active…”
Has psychiatry tamed the “ketamine tiger?” Considerations on its use for depression and anxiety
Rasmussen, K. G. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.01.002 · Cited by 32
Research works printed but not linked: 70
- 10.1177/0269881107083808 · DOI · Paper page
- Torre, 2010, Commentary on Morgan et al (2010) Ketamine abuse: first medical evidence of harms we should confront, Addiction, 105
- 10.1016/j.pain.2011.03.026 · DOI · Paper page
- 10.1016/j.jad.2013.11.014 · DOI · Paper page
- Chen, 2005, Report on a Study on the Cognitive Impairment and other Harmful Effects from Ecstasy and Ketamine Abuse
- 10.1111/j.1360-0443.2011.03576.x · DOI · Paper page
- Thakurta, 2012, Rapid antidepressant response with ketamine: is it the solution to resistant depression?, Indian Journal of Psychological Medicine, 34, 56, 10.4103/0253-7176.96161 · DOI
- 10.1159/000095816 · DOI · Paper page
- 10.1016/j.biopsych.2010.12.015 · DOI · Paper page
- Brenner, 2010, Primary prevention in psychiatry: adult populations, Annals of Clinical Psychiatry, 22
- 10.1007/s00213-014-3543-0 · DOI
- 10.2147/SAR.S15458 · DOI · Paper page
- 10.1126/science.283.5401.464 · doi:10.1126/science.283.5401.464
- Taylor, 2015, The Maudsley Prescribing Guidelines in Psychiatry
- Shram, 2011, Oral ketamine as a positive control in human abuse potential studies, Drug and Alcohol Dependence, 114
- 10.1177/0004867413486842 · DOI · Paper page
- 10.1371/journal.pone.0043947 · DOI · Paper page
- 10.1265/ehpm.11.120 · DOI
- Stahl, 2014, Stahl's Essential Psychopharmacology Prescriber's Guide Antidepressants
- 10.2174/1570159X113119990043 · DOI
- 10.1016/S0193-953X(05)70290-2 · DOI
- 10.3109/15622975.2014.922697 · DOI · Paper page
- 10.1016/S0376-8716(02)00243-0 · DOI · Paper page
- 10.1113/jphysiol.2002.030486 · DOI · Paper page
- 10.1007/s11920-014-0527-z · DOI
- 10.1177/1535370214549531 · DOI
- 10.1177/0269881114527361 · DOI · Paper page
- 10.1111/nyas.12646 · DOI · Paper page
- 10.1007/s00213-010-2062-x · DOI · Paper page
- 10.1017/S1461145709000169 · DOI · Paper page
- 10.4088/JCP.11096su1c.01 · DOI · Paper page
- 2013, Drugs and inhalants
- 10.1016/j.psychres.2013.12.008 · DOI
- 10.1111/j.1360-0443.2011.03648.x · DOI
- 10.1016/S0006-3223(99)00194-8 · DOI
- 10.1176/appi.ajp.162.12.2352 · DOI · Paper page
- Smith, 2011, Drug Misuse Declared: Findings from the 2010/11 British Crime Survey. England and Wales
- 10.1016/j.euroneuro.2011.08.002 · DOI
- 10.1017/S1461145714000649 · DOI · Paper page
- 10.1097/JCP.0000000000000090 · DOI · Paper page
- 10.1176/appi.ajp.2014.14030354 · DOI
- 2003, Emergency Department Trends from the Drug Abuse Warning Network: Final Estimates 1995–2002 (Drug Abuse Warning Network Series: D-24)
- 10.1007/s00787-012-0292-7 · DOI
- Bergman, 1999, Ketamine: review of its pharmacology and its use in pediatric anesthesia, Anesthesia Progress, 46, 10
- 10.1001/archpsyc.1994.03950030035004 · DOI · Paper page
- 2014, Intravenous Ketamine for the Treatment of Mental Health Disorders: A Review of Clinical Effectiveness and Guidelines
- 10.1126/science.1835799 · DOI · Paper page
- Hillhouse, 2014, Dissociable effects of the noncompetitive NMDA receptor antagonists ketamine and MK-801 on intracranial self-stimulation in rats, Psychopharmacology, 13
- Carroll, 1983, Oral d-amphetamine and ketamine self-administration by rhesus monkeys: effects of food deprivation, Journal of Pharmacology and Experimental Therapeutics, 227, 28, 10.1016/S0022-3565(25)22027-4 · DOI
- 10.2217/17520363.3.1.5 · DOI
- Sackeim, 2001, The definition and meaning of treatment-resistant depression, Journal of Clinical Psychiatry, 62
- 10.1111/cns.12103 · DOI · Paper page
- 10.1038/npp.2015.191 · DOI
- Sinner B , Graf BM (2008) Ketamine. In Modern Anesthetics (eds Schuttler J , Schwilden H ) 313–33 (Handbook of Experimental Pharmacology, vol 182). Springer. · DOI · Paper page
- Sokero, 2003, Suicidal ideation and attempts among psychiatric patients with major depressive disorder, Journal of Clinical Psychiatry, 64
- Pappachan, 2014, Multiorgan dysfunction related to chronic ketamine abuse, Proceedings (Baylor University Medical Centre), 27
- Sonawalla, 2002, Placebo response in depression, Dialogues in Clinical Neuroscience, 4, 10.31887/DCNS.2002.4.1/ssonawalla · DOI · Paper page
- 10.1016/S0165-6147(02)02086-2 · DOI
- 10.1080/08897077.2014.935560 · DOI
- Trujillo, 2011, The neurobehavioral pharmacology of ketamine: implications for drug abuse, addiction, and psychiatric disorders, Laboratory Animal Research Journal, 52
- 10.1001/archpsyc.63.8.856 · DOI · Paper page
- 10.1111/j.1749-6632.1988.tb42109.x · DOI
- 10.1016/j.pbb.2013.11.033 · DOI · Paper page
- 10.1016/S0379-0738(03)00261-5 · DOI
- 10.1016/S0893-133X(97)00036-5 · DOI · Paper page
- 10.1097/00000542-197509000-00007 · DOI
- 10.1136/bmj.h4467 · DOI
- 10.1016/S0006-3223(99)00230-9 · DOI · Paper page
- 10.1176/appi.ajp.2014.13101434 · DOI
- 10.1016/0014-2999(93)90147-A · DOI · Paper page
Cited by
Matveychuk, D., Thomas, R. K., Swainson, J., Khullar, A., MacKay, M.-A., Baker, G. B., & Dursun, S. M. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320916657 · Cited by 209
Almeida, R. N. D., Galvão, A. C. D. M., da Silva, F. S., Silva, E. A. D. S., Palhano-Fontes, F., Maia-de-Oliveira, J. P., de Araújo, L.-S. B., Lobão-Soares, B., & Galvão-Coelho, N. L. (2019) · Frontiers in Psychology · doi:10.3389/fpsyg.2019.01234 · Cited by 177
“With careful augmentation of different antidepressants and other treatment modalities, about 9–10% of patients with depression have treatment-resistant depression (Ho and Zhang, 2016).”
BackgroundRong, C., Park, C., Rosenblat, J. D., Subramaniapillai, M., Zuckerman, H., Fus, D., Lee, Y. L., Pan, Z., Brietzke, E., Mansur, R. B., et al. (2018) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph15040771 · Cited by 114
“The medical communities should conduct more research and be more critical of the evidence provided by ketamine trials [10].”
BackgroundVan Amsterdam, J., & Van Den Brink, W. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1949454 · Cited by 44
Metadata
- Authors
- Ho, R. C. M., & Zhang, M. W.
- Venue
- BJPsych Advances
- Publisher
- Royal College of Psychiatrists
- Published
- 2016-07
- Volume
- 22
- Issue
- 4
- Pages
- 222-233
- ISSN
- 2056-4678 (ISSN-L)
- 2056-4686
- OpenAlex
- W2474890852
- Cited by
- 24
- References
- 30
- FWCI
- 1.36
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.